These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12394688)

  • 1. Management of post-chemotherapy residual masses in advanced seminoma.
    Flechon A; Bompas E; Biron P; Droz JP
    J Urol; 2002 Nov; 168(5):1975-9. PubMed ID: 12394688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
    Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
    Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery for a post-chemotherapy residual mass in seminoma.
    Herr HW; Sheinfeld J; Puc HS; Heelan R; Bajorin DF; Mencel P; Bosl GJ; Motzer RJ
    J Urol; 1997 Mar; 157(3):860-2. PubMed ID: 9072586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of advanced seminoma: retrospective study of 96 patients].
    Bompas E; Fléchon A; Biron P; Droz JP
    Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
    Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.
    Puc HS; Heelan R; Mazumdar M; Herr H; Scheinfeld J; Vlamis V; Bajorin DF; Bosl GJ; Mencel P; Motzer RJ
    J Clin Oncol; 1996 Feb; 14(2):454-60. PubMed ID: 8636757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
    Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
    J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
    Fosså SD; Droz JP; Stoter G; Kaye SB; Vermeylen K; Sylvester R
    Br J Cancer; 1995 Mar; 71(3):619-24. PubMed ID: 7880748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual mass following chemotherapy of seminoma.
    Horwich A; Paluchowska B; Norman A; Huddart R; Nicholls J; Fisher C; Husband J; Dearnaley DP
    Ann Oncol; 1997 Jan; 8(1):37-40. PubMed ID: 9093705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of residual masses after chemotherapy in metastatic seminoma.
    Ravi R; Ong J; Oliver RT; Badenoch DF; Fowler CG; Hendry WF
    BJU Int; 1999 Apr; 83(6):649-53. PubMed ID: 10233573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of resections for residual masses after chemotherapy in metastatic testicular tumors.
    Suzuki K; Orikasa S; Hoshi S; Yoshikawa K; Saito S; Ohyama C; Sato M; Kawamura S; Numahata K; Ito A; Tokuyama S
    Int J Urol; 1999 Jun; 6(6):305-13. PubMed ID: 10404307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors.
    Hartmann JT; Schmoll HJ; Kuczyk MA; Candelaria M; Bokemeyer C
    Ann Oncol; 1997 Jun; 8(6):531-8. PubMed ID: 9261521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection.
    Hofmockel G; Gruss A; Theiss M
    Urol Int; 1996; 57(1):38-42. PubMed ID: 8840489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
    Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
    J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
    Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
    Takizawa A; Miura T; Fujinami K; Osada Y
    Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retroperitoneal residual tumor resection after chemotherapy of malignant testicular cancers].
    Albers P
    Aktuelle Urol; 2012 May; 43(3):197-206. PubMed ID: 22639031
    [No Abstract]   [Full Text] [Related]  

  • 19. Cisplatin-based chemotherapy for advanced seminoma: report of 52 cases treated in two institutions.
    Giannis M; Aristotelis B; Vassiliki K; Ioannis A; Konstantinos S; Nikolaos A; Georgios P; Georgios P; Pantelis P; Meletios-Athanasios D
    J Cancer Res Clin Oncol; 2009 Nov; 135(11):1495-500. PubMed ID: 19437039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.
    Motzer R; Bosl G; Heelan R; Fair W; Whitmore W; Sogani P; Herr H; Morse M
    J Clin Oncol; 1987 Jul; 5(7):1064-70. PubMed ID: 3598610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.